The PREVAC consortium (Liberia, Guinea, Mali, and Sierra Leone) includes scientists from PREVAIL, the French research organization Inserm, and from institutions in Africa, the United States, and the United Kingdom. The consortium has now published the results of a large clinical study in West Africa in the New England Journal of Medicine. These results confirm the safety of three different Ebola vaccine regimens and suggest that each regimen induces an immune response that is maintained for up to one year. The study aimed to measure the rapidity, intensity and durability of the immune responses generated by three different Ebola vaccine regimens, including the vaccines mentioned above. Beyond these advances, research on Ebola vaccines must continue, say the investigators.
